Shareholding for the Period Ended December 31, 2017
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here20-01-2018
20-01-2018
Credit Rating
We hereby inform you that ICRA Limited (ICRA) has assigned a long term rating of ICRA A and short term rating of ICRA A1 against the existing ratings of long term rating of CRISIL A-/Positive and short term rating of CRISIL A2+ assigned by CRISIL. This is for your information and doing the needful.11-01-2018
Allotment
We hereby intimate that the Board, in pursuance to the common order passed by National Company Law Tribunal, Bengaluru Bench in C.P (CAA) No.06/BB/2017 and C.P (CAA) No.08/BB/2017 dated 24th November, 2017, confirming the Scheme of Amalgamation of Navya Biologicals Private Limited (Transferor Company) with Shilpa Medicare Limited (Transferee Company), allotted 13,99,994 (Thirteen Lakhs Ninty Nine Thousand nine hundred and ninety four) Equity shares...16-12-2017
Shilpa Medicare slips after USFDA issues 10 observations
The stock slipped 6% to Rs 599 on the BSE in intra-day trade.06-12-2017
Updates
we hereby intimate you that SHILPA MEDICARE LIMITED has received 483 Observations from the United States Food & Drug Administration (USFDA) in relation to SEZ Formulation Facilities situated at Jadcherla, Telangana (near Hyderabad) as under; a) Total 10 observations were cited during the close up meeting. b) 7 observations are improvement in procedures and practices....05-12-2017
Award of Order Receipt of Order
We hereby intimate you that the scheme of merger of Navya Biologicals Private Limited with Shilpa Medicare Limited has been approved by the Hon'ble National Company Law Tribunal, Bengaluru Bench. A copy of the Order is annexed herewith. The Company will take necessary steps to complete the requisite procedural compliances with regard to said merger as required under the Companies Act and SEBI (LODR) Regulations. This is for your information and records.30-11-2017
Newspaper Publication
We are enclosing herewith paper cuttings of the notice published in newspaper viz. Business Standard and Suddimoola (Kannada Daily) on 15th November 2017 with regard to publication of Financial Results for the Second Quarter ended 30th September, 2017. This is for your information and records.16-11-2017
Appointment of Chief Financial Officer (CFO)
Sub: Rectification of Intimation filed under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated 14.11.2017- Reg. Scrip Code: BSE - 530549/ Stock Symbol: NSE - SHILPAMED Due to typographical error, Mr. Sushil Bajaj was mentioned as a Member of the Institute of Company Secretaries of India instead of a Member of the Institute of Chartered Accountants of India....14-11-2017
Financial Results For September 30, 2017
With reference to the captioned subject, Please find the enclosed documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015: 1. Un-Audited Standalone and Consolidated Financial Results for the second quarter ended 30th September, 2017. 2. Limited Review Report on Standalone and Consolidated Financials for the second quarter ended 30th September, 2017. It is further intimated that meeting was commenced at 10:45 A.M. and ended at 2:45 P.M.13-11-2017
Closure of Trading Window
We wish to inform you that a meeting of Board of Directors will be held on Monday, the 13th day of November, 2017 inter alia to consider the Un-audited Financial Results for the Second Quarter ended 30th September, 2017 in compliance of Regulation 33 of the SEBI (LODR) Regulations, 2015. It is further intimated that Trading Window would remain closed from 06/11/2017 to...03-11-2017